<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121169">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095171</url>
  </required_header>
  <id_info>
    <org_study_id>PRX002-CL001</org_study_id>
    <nct_id>NCT02095171</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of PRX002 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neotope Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neotope Biosciences Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single ascending dose study is to determine safety, tolerability, pharmacokinetics and
      immunogenicity of PRX002 in approximately 40 healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as determined by number of subjects with adverse events</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- time of the maximum measured concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- terminal elimination half life (tÂ½)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetics parameters</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- apparent volume of distribution (Vd)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as determined by measurement of anti-PRX002 antibodies</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PRX002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX002</intervention_name>
    <arm_group_label>PRX002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg

          -  Female subjects must be surgically sterile or post-menopausal or if of child-bearing
             potential must use contraception

          -  Male subjects and their partners of childbearing potential must use contraception

        Exclusion Criteria:

          -  Positive test for drug of abuse

          -  Past or current history of alcohol abuse

          -  Positive for hepatitis B, hepatitis C or HIV infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Neumann, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Trials Neotope Biosciences Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Neumann, PhD</last_name>
    <phone>(650) 615-2128</phone>
    <email>theresa.neumann@prothena.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
